Q8
Product Specifications
UNSPSC Description
Q8, an effective antiangiogenic drug, is a CysLt1 antagonist (IC50 of 4.9 μM). Q8 is sufficient to reduce cellular levels of NF-κB and calpain-2 and secreted levels of the proangiogenic proteins intercellular adhesion molecule-1, vascular cell adhesion protein-1, and VEGF[1].
Target Antigen
Leukotriene Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/q8.html
Smiles
OC1=CC=C(O)C=C1/C=C/C2=NC3=CC=CC=C3C=C2.Cl
Molecular Weight
299.75
References & Citations
[1]Clare T Butler, et al. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. J Biol Chem. 2017 Mar 3;292(9):3552-3567.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-127113/Q8-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-127113/
Clinical Information
No Development Reported
CAS Number
1541762-55-3
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GC4109-100mg 100 mg
1,6-Anhydro-3,4-dideoxy-2,2-(ethylenedioxy)-β-D-glycero-hex-3-enopyranose
Ask
View Details 